The rationale behind this development is based on findings demonstrating that while each PI3K isoform has selective roles, they also have synergistic actions in a tumor-intrinsic or extrinsic manner and/or can be re-activated as an adaptive response to PI3K isoform-specific inhibition. The gene discussed is PIK3CB; the disease is neoplasm.